Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharp and Dohme presents new clinical data at ID Week 2017

Merck Sharp and Dohme presents new clinical data at ID Week 2017

10th October 2017

Merck Sharp and Dohme has presented new clinical data on a number of its newest therapies during the recent ID Week 2017 conference in San Diego.

From October 4th to 8th, the company gave 40 scientific data presentations on its established and investigational infectious disease medicines and vaccines, reflecting the latest developments in its antimicrobial research efforts.

These included new data analyses from the pivotal phase III clinical study of letermovir, Merck's investigational antiviral medicine for prophylaxis of cytomegalovirus infection or disease, and the findings of another phase III trial of V212, its investigational vaccine for herpes zoster.

Real-world susceptibility and clinical use data was also shared on the in vitro activity of Zerbaxa, which is indicated for the treatment of adults with complicated urinary tract infections, including pyelonephritis.

Dr Joan Butterton, executive director and section head for antibacterials and cytomegalovirus infectious disease clinical research at Merck Research Laboratories, said: "We remain deeply committed to developing medicines and vaccines that help to prevent and treat serious infectious diseases to help address some of the most pressing public health threats in the world today."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.